Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach

被引：25

作者：

Li, Xiao ^{[1
]}

Chen, Wenmin ^{[1
]}

Tian, Ye ^{[1
]}

Liu, Huiqing ^{[2
]}

Zhan, Peng ^{[1
]}

De Clercq, Erik ^{[3
]}

Pannecouque, Christophe ^{[3
]}

Balzarini, Jan ^{[3
]}

Liu, Xinyong ^{[1
]}

机构：

[1] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Key Lab Chem Biol,Minist Educ, Jinan 250012, Shandong, Peoples R China

[2] Shandong Univ, Sch Med, Inst Pharmacol, Jinan 250012, Shandong, Peoples R China

[3] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Leuven, Belgium

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2014年 / 80卷

基金：

高等学校博士学科点专项科研基金; 中国国家自然科学基金;

关键词：

HIV-1; HIV-2; DAPY; Anti-HIV activities; Structure-activity relationships; Molecular modeling; REVERSE-TRANSCRIPTASE INHIBITORS; ACTIVE ANTIRETROVIRAL THERAPY; BIOLOGICAL EVALUATION; VIROLOGICAL FAILURE; DERIVATIVES; DESIGN; ANALOGS;

D O I：

10.1016/j.ejmech.2014.04.036

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Guided by crystal structures of HIV-1 RT/DAPY complex and molecular modeling studies, a series of novel DAPY derivatives were rationally designed, synthesized and evaluated for their anti-HIV activities. Among them, 16 compounds significantly inhibited HIV-1 IIIB replication with EC50 values lower than 66 nM. Particularly, compound 7a was the most potent inhibitor against HIV-1 wild-type and double RT mutant HIV-1 strain K103N/Y181C, with an EC50 value of 2.5 nM (SI = 13,740) and 0.33 mu M (SI = 107), respectively. Unexpectedly, compound 8c was found to show moderate anti-HIV-2 potency (EC50 = 5.57 mu M). Preliminary structure-activity relationships (SARs) and molecular modeling of these new analogues were also discussed in detail. (C) 2014 Elsevier Masson SAS. All rights reserved.

引用

页码：112 / 121

页数：10

共 50 条

[1] Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing
Zhao, Tong
Meng, Qing
Kang, Dongwei
Ji, Jianbo
De Clercq, Erik
Pannecouque, Christophe
Liu, Xinyong
Zhan, Peng
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 182
[2] Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: Discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach
Wang, Liu
Tian, Ye
Chen, Wenmin
Liu, Hong
Zhan, Peng
Li, Dongyue
Liu, Huiqing
De Clercq, Erik
Pannecouque, Christophe
Liu, Xinyong
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 85 : 293 - 303
[3] Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement
Li, Xiao
Gao, Ping
Huang, Boshi
Zhou, Zhongxia
Yu, Zhao
Yuan, Zheng
Liu, Huiqing
Pannecouque, Christophe
Daelemans, Dirk
De Clercq, Erik
Zhan, Peng
Liu, Xinyong
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 126 : 190 - 201
[4] Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach
Song, Yu'ning
Zhan, Peng
Kang, Dongwei
Li, Xiao
Tian, Ye
Li, Zhenyu
Chen, Xuwang
Chen, Wenmin
Pannecouque, Christophe
De Clercq, Erik
Liu, Xinyong
MEDCHEMCOMM, 2013, 4 (05) : 810 - 816
[5] Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach
Lu, Xueyi
Li, Xiao
Yang, Jiapei
Huang, Boshi
Kang, Dongwei
Zhao, Fabao
Zhou, Zhongxia
De Clercq, Erik
Daelemans, Dirk
Pannecouque, Christophe
Zhan, Peng
Liu, Xinyong
BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (18) : 4424 - 4433
[6] Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1
Huang, Boshi
Kang, Dongwei
Yang, Jiapei
Zhan, Peng
Liu, Xinyong
EXPERT OPINION ON THERAPEUTIC PATENTS, 2016, 26 (02) : 281 - 289
[7] Lead Optimization and Avoidance of Metabolic-perturbing Motif Developing Novel Diarylpyrimidines as Potent HIV-1 NNRTIs
Sun, Yanying
Zhou, Zhenzhen
Feng, Da
Jing, Lanlan
Zhao, Fabao
Wang, Zhao
Zhang, Tao
Lin, Hao
Song, Hao
De Clercq, Erik
Pannecouque, Christophe
Zhan, Peng
Liu, Xinyong
Kang, Dongwei
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (23) : 15608 - 15626
[8] Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach
Li, Xiao
Huang, Boshi
Zhou, Zhongxia
Gao, Ping
Pannecouque, Christophe
Daelemans, Dirk
De Clercq, Erik
Zhan, Peng
Liu, Xinyong
CHEMICAL BIOLOGY & DRUG DESIGN, 2016, 88 (02) : 241 - 253
[9] Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel"
Zhou, Zhongxia
Liu, Tao
Kang, Dongwei
Huo, Zhipeng
Wu, Gaochan
Daelemans, Dirk
De Clercq, Erik
Pannecouque, Christophe
Zhan, Peng
Liu, Xinyong
ORGANIC & BIOMOLECULAR CHEMISTRY, 2018, 16 (06) : 1014 - 1028
[10] Discovery of novel VEGFR-2 inhibitors. Part 5: Exploration of diverse hinge-binding fragments via core-refining approach
Shan, Yuanyuan
Gao, Hongping
Shao, Xiaowei
Wang, Jinfeng
Pan, Xiaoyan
Zhang, Jie
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 103 : 80 - 90

← 1 2 3 4 5 →